Webinar Recordings

1536 DRUG-seq: scaling transcriptomics for high-throughput drug discovery

In this webinar, scientists from Nuvisan and Alithea Genomics will present an end-to-end workflow for transcriptomic screening in 1536-well plates. Combining Nuvisan’s ultra-high-throughput screening capabilities with Alithea Genomics’ MERCURIUS™ DRUG-seq technology, the workflow spans cellular assay development and compound treatment through library preparation, sequencing, and data analysis.

What would you screen if whole-transcriptome profiling ran in 1536-well plates? In this joint webinar, Zuzanna Makowska (Senior Scientist, Nuvisan) and Riccardo Dainese (CBO and co-founder, Alithea Genomics) show how MERCURIUS™ 1536 DRUG-seq brings transcriptomics to screening scale, end-to-end at Nuvisan.

Why 1536 wells?
AI-driven drug discovery needs large perturbation datasets that read biology directly. DRUG-seq reads more than 12,000 named genes per well, without RNA extraction, and pools a whole plate into one library. A 500,000-sample dataset fits on 350 plates in 1536-well format, against 1,400 plates in 384-well format.

What the data shows
Run side by side in three cell lines, the 1536-well format matches the 384-well format: the same demultiplexing rate, more than 12,000 genes per well at 1 million reads, compounds clustering by mode of action, and the same sensitivity for differential gene expression.

What you will learn

  • How the automated 1536-well workflow runs, from cell seeding to one pooled library per plate
  • How to plan a screen: cell model, plates, seeding density, controls, replicates and randomized layouts
  • How deep to sequence, and what 4, 16 or 350 plates can deliver
  • How DRUG-seq and Cell Painting together explain the mechanism behind a phenotype (adipocyte differentiation case study)

Speakers
Zuzanna Makowska – Senior Scientist, Nuvisan
Riccardo Dainese – CBO and co-founder, Alithea Genomics
Moderator: Sophia Shilimindri (Alithea Genomics)

Chapters
0:00 Welcome and agenda
1:36 Alithea Genomics and MERCURIUS™ DRUG-seq
2:36 Why AI-driven drug discovery needs perturbation data
3:15 Comparing readouts: L1000, single-cell RNA-seq, Cell Painting, DRUG-seq
5:16 The missing corner of the chemistry-to-biology map
7:38 How DRUG-seq works: extraction-free, barcoded, pooled
10:11 Why the cell model matters
12:09 What makes DRUG-seq work at scale
13:15 End-to-end 1536 DRUG-seq with Nuvisan
14:47 Nuvisan: drug discovery and sequencing in Berlin
16:46 DRUG-seq at Nuvisan since 2024
17:49 The automated 1536-well workflow
21:10 384 vs 1536 wells: technical performance
22:55 Clustering compounds by mode of action
24:31 Dose response and differential gene expression
26:31 Planning an experiment: cell model, plates, seeding density
29:30 Controls, replicates and randomized layouts
32:41 Perturbations: time point, dose, CRISPR and RNAi
34:34 Sequencing depth and data analysis
36:08 What can you do with 1536 wells?
38:25 Cell models, compound libraries and combined readouts
41:24 Case study: Cell Painting + DRUG-seq in adipocyte differentiation
44:32 Q&A: how many cells per well?
45:45 Q&A: runtime compared with 384-well plates
46:37 Q&A: several plates on one flow cell
47:08 Q&A: primary cells, iPSC-derived cells and 3D models
48:10 Q&A: how many replicates?
49:21 Q&A: sending treated cells to Nuvisan
50:04 Q&A: long-read sequencing and isoforms

Speakers

Riccardo Dainese

CBO and co-founder

Riccardo is the CBO and co-founder of Alithea Genomics.

Before that, he completed his PhD in Bioengineering and Microfluidics at the Swiss Federal Institute of Technology (EPFL) in the Laboratory of Systems Biology and Genetics run by Prof. Bart Deplancke.

During his PhD Riccardo has worked on and co-developed a number of microvalve-based and droplet-based microfluidic devices with genomic applications, such as Smile-seq, FloChIP, DisCO all of which have been patented separately and published in top-tier journals such as Nature Methods and PNAS.

Before his PhD, Riccardo obtained a Master’s degree in Nanotechnology at Chalmers University (Goteborg, Sweden) and a Bachelor’s in Biomedical Engineering at the Politecnico di Torino (Italy).

Zuzanna Makowska

Senior Scientist

Zuzanna Makowska is a Senior Scientist at Nuvisan. She has a background in molecular cell biology and expertise in sequencing technologies.

Zuzanna works at the interface of high-dimensional data generation and analysis, establishing and optimising complex workflows in the fast-moving field of genomics and next generation sequencing.

At Nuvisan, she supports customer projects involving single-cell and bulk sequencing, DRUG-seq and CRISPR screening. Her work spans study planning, experimental design, data generation and analysis.

1536 DRUG-seq webinar with Nuvisan

Ready to talk about your next RNA-seq study?

Tell us about your project and we will help you find the right approach.